ATE327329T1 - Tie ligand-homologuen - Google Patents

Tie ligand-homologuen

Info

Publication number
ATE327329T1
ATE327329T1 AT98946987T AT98946987T ATE327329T1 AT E327329 T1 ATE327329 T1 AT E327329T1 AT 98946987 T AT98946987 T AT 98946987T AT 98946987 T AT98946987 T AT 98946987T AT E327329 T1 ATE327329 T1 AT E327329T1
Authority
AT
Austria
Prior art keywords
tie ligand
nucleic acid
ligand homologues
acid molecules
protein
Prior art date
Application number
AT98946987T
Other languages
English (en)
Inventor
Paul J Godowski
Austin L Gurney
Kenneth Hillan
David Botstein
Audrey Goddard
Margaret Roy
Napoleone Ferrara
Daniel Tumas
Ralph Schwall
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/933,821 external-priority patent/US5972338A/en
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE327329T1 publication Critical patent/ATE327329T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT98946987T 1997-09-19 1998-09-14 Tie ligand-homologuen ATE327329T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/933,821 US5972338A (en) 1997-09-19 1997-09-19 Tie ligands homologues
US08/960,507 US6057435A (en) 1997-09-19 1997-10-29 Tie ligand homologues

Publications (1)

Publication Number Publication Date
ATE327329T1 true ATE327329T1 (de) 2006-06-15

Family

ID=27130048

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98946987T ATE327329T1 (de) 1997-09-19 1998-09-14 Tie ligand-homologuen

Country Status (15)

Country Link
US (3) US6057435A (de)
EP (4) EP1015585B1 (de)
JP (4) JP2001517437A (de)
KR (4) KR100692333B1 (de)
AT (1) ATE327329T1 (de)
AU (1) AU756449B2 (de)
CA (1) CA2304129A1 (de)
CY (1) CY1105161T1 (de)
DE (1) DE69834649T2 (de)
DK (1) DK1015585T3 (de)
ES (1) ES2268790T3 (de)
IL (2) IL134648A0 (de)
NZ (1) NZ502946A (de)
PT (1) PT1015585E (de)
WO (1) WO1999015653A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034800A1 (en) * 1999-11-12 2001-05-17 Human Genome Sciences, Inc. 19 human secreted proteins
US6350450B1 (en) * 1997-09-19 2002-02-26 Genentech, Inc. TIE ligand homologue antibody
US6057435A (en) 1997-09-19 2000-05-02 Genentech, Inc. Tie ligand homologues
US5972338A (en) * 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
CA2313804A1 (en) * 1997-12-19 1999-07-01 Regeneron Pharmaceuticals, Inc. Receptor tyrosine kinase, ar-1, is a regulator of angiogenesis
AU2493699A (en) * 1998-02-04 1999-08-23 Zymogenetics Inc. Angiopoietin homolog zapo3, dna encoding it, and method of making it
WO1999055869A1 (en) * 1998-04-27 1999-11-04 Zymogenetics, Inc. Novel polypeptide growth factors and materials and methods for making them
AU4320499A (en) * 1998-06-02 1999-12-20 Eli Lilly And Company Angiopoietin related gene sequence scarface 1
SV1999000069A (es) * 1998-06-02 2000-04-11 Lilly Co Eli Angiopoyetina relacionada con secuencia del gen 3 en la cicatrizacion de la cara ref. x-12261
AU4643699A (en) * 1998-06-24 2000-01-10 Compugen Ltd. Angiopoietin-like growth factor sequences
CA2331789C (en) * 1998-07-13 2013-09-10 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US6818213B1 (en) * 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
US6406693B1 (en) 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
WO2000002584A2 (en) 1998-07-13 2000-01-20 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
AU5081899A (en) * 1998-07-20 2000-02-14 Curagen Corporation Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
AU5210899A (en) * 1998-07-24 2000-02-14 Eli Lilly And Company Angiopoietin related gene sequence scarface 2
AU5472899A (en) * 1998-08-20 2000-03-14 Incyte Pharmaceuticals, Inc. Human angiopoietin-3
US6537554B1 (en) 1998-09-10 2003-03-25 Curagen Corporation Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
US20050148101A1 (en) * 1999-01-23 2005-07-07 Bamdad Cynthia C. Interaction of colloid-immobilized species with species on non-colloidal structures
EP1157111A1 (de) * 1999-03-02 2001-11-28 Regeneron Pharmaceuticals, Inc. Angiopoietin-ähnliches protein und dessen nukleinsäuren
KR20010104373A (ko) * 1999-03-08 2001-11-24 제넨테크, 인크. 혈관신생 및 심혈관형성의 촉진 또는 억제 방법
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US6887468B1 (en) 1999-04-28 2005-05-03 Board Of Regents, The University Of Texas System Antibody kits for selectively inhibiting VEGF
ATE449109T1 (de) * 1999-06-15 2009-12-15 Genentech Inc Sekretierte und transmembran-polypeptide sowie nukleinsäuren zu deren kodierung
CA2377788A1 (en) * 1999-07-02 2001-01-11 Bayer Ag Methods for modulating angiogenesis by using the anti-angiogenic angiotensin-7 and polynucleotides encoding therefor
US6835381B1 (en) 1999-07-02 2004-12-28 Bayer Ag Methods for modulating angiogenesis by using the anti-angiogenic angiotensin-7 and polynucleotides encoding therefor
WO2001003735A1 (en) * 1999-07-12 2001-01-18 Maine Medical Center Research Institute Cancer treatment using angiopoietins targeted to aminophospholipids
DE60035693T2 (de) * 1999-07-20 2008-05-15 Genentech, Inc., South San Francisco Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
WO2001029085A2 (en) * 1999-10-21 2001-04-26 Royal Netherlands Academy Of Arts And Sciences Cdt6 can inhibit angiogenesis and tumor growth, and can induce or enhance the formation of structures containing collagen v
EP1381440B1 (de) * 2000-10-03 2013-01-30 Minerva Biotechnologies Corporation Miniaturisierter druckabfall-filter und verfahren unter verwendung desselben
WO2003062373A2 (en) * 2001-10-18 2003-07-31 The Children's Hospital Of Philadelphia Methods and materials for the recruitment of endothelial cells
US20050123925A1 (en) * 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
JPWO2003083114A1 (ja) * 2002-03-28 2005-08-04 アステラス製薬株式会社 アンジオポエチン関連増殖因子
EP1593740A4 (de) * 2003-06-06 2006-12-06 Astellas Pharma Inc Verfahren zum screening von medizin gegen obesität und obesität-tiermodell
US7871610B2 (en) * 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
EP1656392A2 (de) * 2003-08-12 2006-05-17 Dyax Corp. Tie-1 bindende liganden
US7485297B2 (en) * 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
ZA200702321B (en) * 2004-08-25 2009-09-30 Genentech Inc Novel gene disruptions, compositions and methods relating thereto
CA2589538A1 (en) * 2004-12-03 2006-06-08 Astellas Pharma Inc. Method of screening antiobesity agents
WO2006066071A2 (en) * 2004-12-17 2006-06-22 Mayo Foundation For Medical Education And Research Prognosis of renal cell carcinoma
WO2008089070A2 (en) * 2007-01-12 2008-07-24 Dyax Corp. Combination therapy for the treatment of cancer
US20090104210A1 (en) * 2007-10-17 2009-04-23 Tota Michael R Peptide compounds for treating obesity and insulin resistance
AU2009262199B2 (en) 2008-06-27 2012-08-09 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
EP2494362B1 (de) 2009-10-26 2016-06-08 Externautics S.p.A. Prostatakrebs markers und methoden deren verwendung
EP2494361B2 (de) 2009-10-26 2019-01-09 Externautics S.p.A. Ovarialtumormarker und verfahren zu ihrer verwendung
EP2494351B1 (de) * 2009-10-26 2016-06-08 Externautics S.p.A. Kolon- und rektaltumormarker sowie verfahren zu ihrer verwendung
KR101109486B1 (ko) * 2009-10-29 2012-01-31 현대제철 주식회사 크레인 그래브용 체결장치

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955291A (en) * 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof
JPH07506242A (ja) * 1992-01-09 1995-07-13 ヘルシンキ　ユニバーシティ　ホルディング　リミテッド Ｔｉｅ，新規内皮細胞受容体チロシンキナーゼ
AU4651893A (en) * 1992-06-26 1994-01-24 Immunex Corporation Novel tyrosine kinase
AU8143094A (en) * 1993-11-12 1995-05-29 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. (tie-2), a novel receptor tyrosine kinase
US5643755A (en) * 1994-10-07 1997-07-01 Regeneron Pharmaceuticals Inc. Nucleic acid encoding tie-2 ligand
AUPM379494A0 (en) * 1994-02-10 1994-03-03 Ludwig Institute For Cancer Research Immunointeractive molecules - ii
WO1996009381A1 (en) * 1994-09-22 1996-03-28 Helsinki University Licensing Ltd. Oy Promoter for the receptor tyrosine kinase, tie
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US5650490A (en) * 1994-10-07 1997-07-22 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 2
AU3826295A (en) * 1994-10-13 1996-05-06 Boeing Company, The Jet engine fan noise reduction system utilizing electro pneumatic transducers
AU715621B2 (en) * 1995-04-06 2000-02-03 Regeneron Pharmaceuticals, Inc. TIE-2 ligands, methods of making and uses thereof
US5851797A (en) * 1996-06-19 1998-12-22 Regeneron Pharmaceuticals, Inc. Tie ligand-3, methods of making and uses thereof
DK0939809T3 (da) * 1996-06-19 2003-07-21 Regeneron Pharma TIE-2 receptor-ligand (TIE ligand-4) og dens anvendelse
US5972338A (en) 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
US6057435A (en) 1997-09-19 2000-05-02 Genentech, Inc. Tie ligand homologues
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues

Also Published As

Publication number Publication date
ES2268790T3 (es) 2007-03-16
DE69834649T2 (de) 2007-05-03
WO1999015653A2 (en) 1999-04-01
KR100692333B1 (ko) 2007-03-14
KR20060060060A (ko) 2006-06-02
JP2004129656A (ja) 2004-04-30
DK1015585T3 (da) 2006-10-02
IL134648A (en) 2007-08-19
US6551822B1 (en) 2003-04-22
EP1015585A2 (de) 2000-07-05
KR100692336B1 (ko) 2007-03-14
KR100692335B1 (ko) 2007-03-13
DE69834649D1 (de) 2006-06-29
JP2004113239A (ja) 2004-04-15
JP2004097224A (ja) 2004-04-02
EP1724349A1 (de) 2006-11-22
KR20060060061A (ko) 2006-06-02
IL134648A0 (en) 2001-04-30
AU756449B2 (en) 2003-01-16
JP2001517437A (ja) 2001-10-09
CY1105161T1 (el) 2009-11-04
AU9388098A (en) 1999-04-12
KR20010024146A (ko) 2001-03-26
EP1696030A1 (de) 2006-08-30
CA2304129A1 (en) 1999-04-01
NZ502946A (en) 2001-11-30
PT1015585E (pt) 2006-10-31
US6057435A (en) 2000-05-02
EP1696029A1 (de) 2006-08-30
WO1999015653A3 (en) 1999-05-20
EP1015585B1 (de) 2006-05-24
US6413770B1 (en) 2002-07-02
KR100692334B1 (ko) 2007-03-14
KR20060060062A (ko) 2006-06-02

Similar Documents

Publication Publication Date Title
DE69834649D1 (de) Tie ligand-homologuen
PT1015586E (pt) Homologos de ligandos do receptor tirosina-quinase tie
DK1095140T3 (da) Neurotrofe faktorer
DK0765394T3 (da) Oprensede Myceliopthora-laccaser og nukleinsyrer der koder for disse
WO2001075067A8 (en) Novel nucleic acids and polypeptides
WO2001057188A3 (en) Novel nucleic acids and polypeptides
WO2001057190A3 (en) Novel nucleic acids and polypeptides
HK1120556A1 (en) Neurotrophic factors
DE69839444D1 (de) Smad 6 und dessen anwendungen
WO2002077263A3 (en) Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon
WO2001079449A3 (en) Novel nucleic acids and polypeptides
ATE320496T1 (de) Testisspezifische, menschliche proteinase, svph1- 8
WO2001075093A8 (en) Novel nucleic acids and polypeptides
EA200100110A1 (ru) Нейротрофические факторы
DE69103001D1 (de) Dns-sequenz, die für galactoprotein b3 kodiert.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1015585

Country of ref document: EP